• darkblurbg

    Developing precision therapies

    for type 1 diabetes

    VIDEO
  • darkblurbg

    Intralymphatic immunotherapy

    with Diamyd®

    VIDEO

Available positions at Diamyd Medical

We welcome candidates with relevant experience to join our entrepreneurial and collaborative team.

Read More

The scientific rational and evidence supporting our therapeutic diabetes vaccine Diamyd® was further strengthened the past quarter with three articles published in peer-reviewed scientific journals.

Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Quarterly Report 3 21/22

Company Presentation

 June 22, 2022
Download PDF

Calendar

 Dates for financial information and other events
October 5, 2022
Year-End Report
Year-End Report 2021/2022
October 24 − October 26, 2022
BIO-Europe
BIO-Europe Leipzig, Germany.
November 10, 2022
Annual Report
Annual Report 2021/2022
December 1, 2022
Annual General Meeting
Annual General Meeting 2021/2022
January 25, 2023
Quarterly Report I
Quarterly Report 1 2022/2023
April 5, 2023
Quarterly Report II
Quarterly Report 2 2022/2023
June 28, 2023
Quarterly Report III
Quarterly Report 3 2022/2023
October 11, 2023
Year-end report
Year-end report 2022/2023

THE COMPANY

Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)


Read More

Order GAD for preclinical research

ORDER

Annual Report

  December 21, 2021
Annual Report cover image
Download

Contact Us

Diamyd Medical AB (publ)
Box 7349, SE-103 90 Stockholm, Sweden

Visiting address:
Kungsgatan 29, SE-111 56 Stockholm, Sweden
+46 8 661 00 26
+46 8 661 63 68

Subscribe

   

Follow Us

  ©
GAD PRODUCTS
Order GAD for preclinical research